Analyst awaits data on Wyeth-Elan Alzheimer's drug

kavin submitted, created time 5 months 3 days (money.cnn.com)

By the end of the month, a Cowen and Co. analyst says, Wyeth and Elan Corp. PLC will report clinical trial data for a new kind of Alzheimer's disease treatment _ one that could slow the progress of the disease rather than fighting its symptoms.

Analyst Ian Sanderson calls the test results for bapineuzumab "one of the most anticipated phase II trials in pharmaceutical industry history." He expects Elan and Wyeth to report their findings by the end of June.

The Alzheimer's treatment market is led by four drugs: Pfizer Inc.'s Aricept, Forest Laboratories Inc

1 comment | Blog It | Email It | Keywords: beta-amyloid 42 bapineuzumab LY450139 Alzheimers disease Alzheimers